Capromab - Cytogen Corporation
Alternative Names: 111In CYT 356; Capromab pendetide; CYT 356; indium (111In) labeled capromab pendetide; Indium-111-CYT-356; lndium-CYT-356; ProstaScintLatest Information Update: 24 Mar 2021
At a glance
- Originator Cytogen Corporation
- Class Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
- Mechanism of Action Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Prostate cancer
Most Recent Events
- 22 Mar 2021 Neos Therapeutics has merged with Aytu BioScience to form Aytu BioPharma
- 01 Apr 2019 Hybridyne Imaging Technologies completes a clinical trial in Prostate cancer (Diagnosis) in Canada (NCT02786459)
- 06 Jun 2016 Hybridyne Imaging Technologies initiates enrolment in a clinical trial in Prostate cancer (Diagnosis) in Canada